Mathieu Pieronne
Investment director, venture capital life sciences at Andera Partners- Claim this Profile
Click to upgrade to our gold package
for the full feature experience.
-
Anglais -
Topline Score
Bio
LinkedIn User
During his 6-month internship, Mathieu has shown a very broad spectrum of qualities. His background in Biology did not stop him from tackling complex mechanical problems in Materials Science. He is very dedicated, focused, and always keeps things simple so as to better and faster integrate solutions in an applied, clinical context. His interpersonal skills and curiosity not only reinforced the team spirit of the lab, but also led him to establish new collaborations that opened many perspectives in our lab. His communication skills, his deep scientific knowledge as well as his thorough understanding of the current clinical and economical issues in regenerative medicine let me think that Mathieu will surely be one of the future leaders in the management of innovative biomedical technologies.
LinkedIn User
During his 6-month internship, Mathieu has shown a very broad spectrum of qualities. His background in Biology did not stop him from tackling complex mechanical problems in Materials Science. He is very dedicated, focused, and always keeps things simple so as to better and faster integrate solutions in an applied, clinical context. His interpersonal skills and curiosity not only reinforced the team spirit of the lab, but also led him to establish new collaborations that opened many perspectives in our lab. His communication skills, his deep scientific knowledge as well as his thorough understanding of the current clinical and economical issues in regenerative medicine let me think that Mathieu will surely be one of the future leaders in the management of innovative biomedical technologies.
LinkedIn User
During his 6-month internship, Mathieu has shown a very broad spectrum of qualities. His background in Biology did not stop him from tackling complex mechanical problems in Materials Science. He is very dedicated, focused, and always keeps things simple so as to better and faster integrate solutions in an applied, clinical context. His interpersonal skills and curiosity not only reinforced the team spirit of the lab, but also led him to establish new collaborations that opened many perspectives in our lab. His communication skills, his deep scientific knowledge as well as his thorough understanding of the current clinical and economical issues in regenerative medicine let me think that Mathieu will surely be one of the future leaders in the management of innovative biomedical technologies.
LinkedIn User
During his 6-month internship, Mathieu has shown a very broad spectrum of qualities. His background in Biology did not stop him from tackling complex mechanical problems in Materials Science. He is very dedicated, focused, and always keeps things simple so as to better and faster integrate solutions in an applied, clinical context. His interpersonal skills and curiosity not only reinforced the team spirit of the lab, but also led him to establish new collaborations that opened many perspectives in our lab. His communication skills, his deep scientific knowledge as well as his thorough understanding of the current clinical and economical issues in regenerative medicine let me think that Mathieu will surely be one of the future leaders in the management of innovative biomedical technologies.
Credentials
-
Certification AMF
-Jan, 2016- Nov, 2024
Experience
-
Andera Partners
-
France
-
Venture Capital and Private Equity Principals
-
1 - 100 Employee
-
Investment director, venture capital life sciences
-
May 2014 - Present
Investment director: April 2021 - Investment manager: April 2018 - April 2021 Analyst: April 2015 - April 2018 Intern: May 2014 - April 2015 Deal list: BioVentrix series A (2023), Sonivie series C (2023), Amolyt series B (2021), AM Pharma (2019), HighLife series B (2018), T-Knife seed round (2018), Dynacure series B (2018), Tricares series B (2018), Crescendo Biologics (2018), GamaMabs (2015) Board positions: Sonivie (observer), HighLife (observer), MedLumics… Show more Investment director: April 2021 - Investment manager: April 2018 - April 2021 Analyst: April 2015 - April 2018 Intern: May 2014 - April 2015 Deal list: BioVentrix series A (2023), Sonivie series C (2023), Amolyt series B (2021), AM Pharma (2019), HighLife series B (2018), T-Knife seed round (2018), Dynacure series B (2018), Tricares series B (2018), Crescendo Biologics (2018), GamaMabs (2015) Board positions: Sonivie (observer), HighLife (observer), MedLumics (observer) Scientific, business and financial analysis of worldwide Medtech and Biotech opportunities from prototype/lead optimisation to late clinical development stage for direct investments. • Carried out due-diligence: technological, strategic and intellectual property assessment • Performed scientific analyzes of deal opportunities • Realized Investment Notes for the Investment Committee • Appointed as board observer and invited guest to multiple boards • Worked on multiple reinvestments (convertible loans, internal and external equity rounds) of portfolio companies • Worked with an international team on a daily basis • Participated in reporting to the limited partners Show less Investment director: April 2021 - Investment manager: April 2018 - April 2021 Analyst: April 2015 - April 2018 Intern: May 2014 - April 2015 Deal list: BioVentrix series A (2023), Sonivie series C (2023), Amolyt series B (2021), AM Pharma (2019), HighLife series B (2018), T-Knife seed round (2018), Dynacure series B (2018), Tricares series B (2018), Crescendo Biologics (2018), GamaMabs (2015) Board positions: Sonivie (observer), HighLife (observer), MedLumics… Show more Investment director: April 2021 - Investment manager: April 2018 - April 2021 Analyst: April 2015 - April 2018 Intern: May 2014 - April 2015 Deal list: BioVentrix series A (2023), Sonivie series C (2023), Amolyt series B (2021), AM Pharma (2019), HighLife series B (2018), T-Knife seed round (2018), Dynacure series B (2018), Tricares series B (2018), Crescendo Biologics (2018), GamaMabs (2015) Board positions: Sonivie (observer), HighLife (observer), MedLumics (observer) Scientific, business and financial analysis of worldwide Medtech and Biotech opportunities from prototype/lead optimisation to late clinical development stage for direct investments. • Carried out due-diligence: technological, strategic and intellectual property assessment • Performed scientific analyzes of deal opportunities • Realized Investment Notes for the Investment Committee • Appointed as board observer and invited guest to multiple boards • Worked on multiple reinvestments (convertible loans, internal and external equity rounds) of portfolio companies • Worked with an international team on a daily basis • Participated in reporting to the limited partners Show less
-
-
-
Université Paris Cité
-
France
-
Higher Education
-
700 & Above Employee
-
Lecturer
-
2017 - 2019
Introduction to venture capital to students of the Chair of innovation management & healthcare performance Introduction to venture capital to students of the Chair of innovation management & healthcare performance
-
-
-
INSERM
-
France
-
Research Services
-
700 & Above Employee
-
Intern
-
Jan 2013 - Jul 2013
Dévelopment et optimisation de patchs cardiaques ensemencés avec des progéniteurs cardiaques dérivés de cellules souches embryonnaires humaines pour le traitement de l'insuffisance cardiaque. Participation à l'essai clinique ESCORT. Development and optimisation of cardiac patches seeded with human embryonic stem cell-derived cardiac progenitors for heart regeneration. ESCORT clinical trial phase 1. Publication: Mechanical characterization of new clinically relevant fibrin-based… Show more Dévelopment et optimisation de patchs cardiaques ensemencés avec des progéniteurs cardiaques dérivés de cellules souches embryonnaires humaines pour le traitement de l'insuffisance cardiaque. Participation à l'essai clinique ESCORT. Development and optimisation of cardiac patches seeded with human embryonic stem cell-derived cardiac progenitors for heart regeneration. ESCORT clinical trial phase 1. Publication: Mechanical characterization of new clinically relevant fibrin-based hydrogels for heart repair using shear wave ultrasound elastography Abstract Materials Research Society Meeting Fall 2013 Principal investigator: Pr. Philippe Menasché Show less Dévelopment et optimisation de patchs cardiaques ensemencés avec des progéniteurs cardiaques dérivés de cellules souches embryonnaires humaines pour le traitement de l'insuffisance cardiaque. Participation à l'essai clinique ESCORT. Development and optimisation of cardiac patches seeded with human embryonic stem cell-derived cardiac progenitors for heart regeneration. ESCORT clinical trial phase 1. Publication: Mechanical characterization of new clinically relevant fibrin-based… Show more Dévelopment et optimisation de patchs cardiaques ensemencés avec des progéniteurs cardiaques dérivés de cellules souches embryonnaires humaines pour le traitement de l'insuffisance cardiaque. Participation à l'essai clinique ESCORT. Development and optimisation of cardiac patches seeded with human embryonic stem cell-derived cardiac progenitors for heart regeneration. ESCORT clinical trial phase 1. Publication: Mechanical characterization of new clinically relevant fibrin-based hydrogels for heart repair using shear wave ultrasound elastography Abstract Materials Research Society Meeting Fall 2013 Principal investigator: Pr. Philippe Menasché Show less
-
-
-
INSERM
-
France
-
Research Services
-
700 & Above Employee
-
Intern
-
Apr 2012 - Jun 2012
Equipe 10. Percutaneous Arterial Repair. Etude des facteurs de remodelage matriciel impliqués dans le développement de l'anévrysme de l'aorte abdominale. Analyse des interactions entre le tissus hôte et le produit de thérapie cellulaire. Study of aortic abdominal aneurysm treatment by gingival cell therapy. Principal investigator: Pr. Antoine Lafont Equipe 10. Percutaneous Arterial Repair. Etude des facteurs de remodelage matriciel impliqués dans le développement de l'anévrysme de l'aorte abdominale. Analyse des interactions entre le tissus hôte et le produit de thérapie cellulaire. Study of aortic abdominal aneurysm treatment by gingival cell therapy. Principal investigator: Pr. Antoine Lafont
-
-
-
INSERM UMRS1138
-
Think Tanks
-
1 - 100 Employee
-
Intern
-
Jun 2010 - Jun 2010
Etude des facteurs prédisposants au syndrome hémolytique et urémique atypique. Study of predisposing factors to atypical hemolytic uremic syndrome. Etude des facteurs prédisposants au syndrome hémolytique et urémique atypique. Study of predisposing factors to atypical hemolytic uremic syndrome.
-
-
-
INSERM U791
-
Hôpital Necker Enfant Malade
-
Intern
-
May 2009 - May 2009
Diagnostic pré et post natal. Génétique médicale. Pre-and postnatal diagnosis. Medical genetics. Diagnostic pré et post natal. Génétique médicale. Pre-and postnatal diagnosis. Medical genetics.
-
-
Education
-
2013 - 2014
ESSEC - ESSEC Business School
Advanced Master - Strategy and Management of International Business -
2012 - 2013
Ecole nationale supérieure d'Arts et Métiers
Master of Science (M.Sc.) BioMedical Engineering, Biomechanics-Biomaterials, Biomaterials, Biotherapies -
2011 - 2012
Université Paris Descartes
Master 1, Biologie Cellulaire Physiologie Pathologie -
2007 - 2010
Université Paris Descartes
Licence, Sciences du vivant
Community
